An observational study in Community-acquired Pneumonia, sponsored by Nordsjaellands Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-29.
Sponsored by Nordsjaellands Hospital · Observational
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Nordsjaellands Hospital is the lead sponsor of 88 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults (≥18 years) admitted with community-acquired pneumonia
Infiltrate on chest radiograph plus one or more of the following:
Exclusion Criteria:
Adults over 18 years old admitted with confirmed community-acquired pneumonia.
Other: No intervention
Obervational
Number of death from any causes
Assessed through patient files
Time frame: From date of admission until the day of death from any causes, up to 24 months
Number of participants who develop diabetes
Assessed through patient files and the national registers
Time frame: Up to 24 months
Length of hospital stay
Through patient files
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Oral glucose tolerance test
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6-month
Number of participants who are readmitted
Through patient files
Time frame: Up to 6 months
Facal sample to assess changes in microbiome
Time frame: Day 1, 1 month and 6 months
Urine samples to assess metabolomics
Time frame: Day 1, 1 month and 6 months
Physical activity monitoring (measured by the AX3 accelerometers)
Time frame: During admission (up to 7 days), 14 days from discharge (an average of 5 days)
Self-reported physical activity by scoring of the international physical activity questionnaire (IPAQ)
Time frame: Day 1
Muscle strength (measured by hand grip test)
Time frame: Day 1, discharge (an average of 5 days), 1 months and 6 months
Muscle strength (measured by 30-sec chair stand test)
Time frame: Day 1 and discharge (an average of 5 days)
Functional capacity (measured by 6-minutes walking test)
Time frame: Day 1 and discharge (an average of 5 days)
Activities of daily living (measured by Barthel100)
Time frame: Discharge (an average of 5 days)
BMI
Weight (kilograms) and height (cm) will be combined to report BMI in kg/m\^2
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Waist circumference (measured in cm)
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Body composition analysis (measured by DEXA scans)
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Body composition analysis (measured by bioimpedance)
Time frame: Daily during admission, discharge (an average of 5 days), 1 month and 6 months
Nutritional status (measured by NRS2002)
Time frame: Day 1
Concentration of p-phosphate (mmol/l), p-sodium (mmol/l), p-carbamide (mmol/l), p-potassium (mmol/l)
Blood sampling
Time frame: Daily during admission, 1 month and 6 months
Concentration of pro- and anti-inflammatory cytokines (IL-6, Il-1ra, IL-18, IL-10, TNF-alpha)
Time frame: Daily during admission, discharge (an average of 5 days), 1 month and 6 months
Immune cell phenotyping to identify cell counts various T-cells, B-cells, NK-cells and monocytes
Flow cytometry on whole blood
Time frame: Day 1 and discharge (an average of 5 days)
Concentration of blood lipids
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Scoring of the Charlson Comorbidity Index to predict 10-year survival
Scale ranges from 0 to 33 points to predict survival (%)
Time frame: Day 1
Oral status (determined by revised oral assessment guide)
Time frame: Day 1
Dysphagia screening (eating assessment tool 10)
Time frame: Day 1
Quality of life (EQ-5D-5L)
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Glycemic control during oral glucose tolerance test
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Glucagon concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Insulin concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
C-peptide concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
GLP-1 concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
GLP-2 concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
GIP concentration during oral glucose tolerance test
Blood sampling
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Insulin sensitivity index (Matsuda) based on oral glucose tolerance test
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Insulin secretion index based on oral glucose tolerance test
Time frame: Day 1, discharge (an average of 5 days), 1 month and 6 months
Concentration of galectin-3 (ng/ml), sST2 (ng/ml), and troponins (ng/ml)
Blood sampling
Time frame: Daily during admission, 1 month and 6 months
Concentration of NT-proBNP (ng/l)
Blood sampling
Time frame: Daily during admission, 1 month and 6 months
Z-value of left ventricle (LV) out of echocardiography
Z-value LV
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Z-value of right ventricle (RV) out of echocardiography
Z-value RV
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Z-value of left atrium (LA) out of echocardiography
Z-value LA
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Shortening fraction (SF) measured in echocardiography
SF (%)
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Ejection fraction (EF) measured in echocardiography
EF (%)
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Valvular insufficiency measured in echocardiography
Aorta valve regurgitation, pulmonary valve regurgitation, tricuspid valve regurgitation and mitral valve regurgitation (no, minimal, moderate, severe)
Time frame: Discharge (an average of 5 days), 1 month and 6 months
Heart rate of 12-lead resting ECG
bpm
Time frame: Daily during admission (up to 5 days)
Rhythm during 12-lead resting ECG
Sinus rhythm yes/no
Time frame: Daily during admission (up to 5 days)
Axis of the QRS complex out of the 12-lead resting ECG
Degree
Time frame: Daily during admission (up to 5 days)
Duration of PQ interval out of the 12-lead resting ECG
ms
Time frame: Daily during admission (up to 5 days)
Duration of the QRS complex out of the 12-lead resting ECG
ms
Time frame: Daily during admission (up to 5 days)
Number of cardiac events
Assessed through patient files and the national registers
Time frame: From date of admission up to 24 months
Sputum samples to assess glucose and lactate concentration (measured by ABL)
Time frame: On admission, 1 month and 6 months
Sputum samples to evaluate drug resistance and O2 content
Time frame: On admission, 1 month and 6 months
Forced vital capacity (FVC) during spirometry
Litre
Time frame: Discharge (an average of 5 days)
Forced expiratory volume in 1 second (FEV1) during spirometry
Litre
Time frame: Discharge (an average of 5 days)
FEV1% predicted during spirometry
Time frame: Discharge (an average of 5 days)
Chest x-ray to image inflammation of the lungs
Time frame: On admission, 1 month and 6 months
Early Warning Score (EWS) to identify patients at risk of deterioration in hospital
Time frame: Daily during admission (up to 5 days)
HbA1c to assess the average blood glucose levels 3 months before admission
Time frame: Day 1
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nordsjaellands Hospital